Persistent Asset Partners Ltd Makes New $468,000 Investment in Viridian Therapeutics, Inc. $VRDN

Persistent Asset Partners Ltd purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the second quarter, Holdings Channel.com reports. The fund purchased 25,490 shares of the company’s stock, valued at approximately $468,000.

Other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after purchasing an additional 876 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Viridian Therapeutics by 33.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after purchasing an additional 14,788 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in Viridian Therapeutics during the 2nd quarter valued at approximately $187,000. Finally, Creative Planning acquired a new position in Viridian Therapeutics during the 2nd quarter valued at approximately $179,000.

Viridian Therapeutics Stock Performance

VRDN opened at $22.08 on Monday. Viridian Therapeutics, Inc. has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $2.50 billion, a PE ratio of -6.55 and a beta of 0.91. The firm has a 50 day moving average of $19.01 and a two-hundred day moving average of $21.23.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VRDN shares. Weiss Ratings cut shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Truist Financial boosted their price objective on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wells Fargo & Company raised Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $20.00 to $31.00 in a research report on Monday, June 29th. Royal Bank Of Canada raised their target price on Viridian Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Finally, Evercore set a $26.00 price target on Viridian Therapeutics in a research report on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.93.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.